Minnesota HF4064 directs the Commissioner of Health to study and report on activities to support innovations in cell and gene therapy for rare.

Minnesota HF4064 mandates the Commissioner of Health to conduct a comprehensive study on the state's capacity for rare disease cell and gene therapy research, development, delivery, and access. The study will assess current infrastructure, opportunities for innovation, clinical trial capacity, biomanufacturing, workforce needs, and policies affecting coverage and payment. The commissioner must consult with various stakeholders, including the University of Minnesota and the Minnesota Rare Disease Advisory Council.

Minnesota HF4064 directs the Commissioner of Health to study and report on activities to support innovations in cell and gene therapy for rare.

Minnesota HF4064 mandates the Commissioner of Health to conduct a comprehensive study on the state's capacity for rare disease cell and gene therapy research, development, delivery, and access. The study will assess current infrastructure, opportunities for innovation, clinical trial capacity, biomanufacturing, workforce needs, and policies affecting coverage and payment. The commissioner must consult with various stakeholders, including the University of Minnesota and the Minnesota Rare Disease Advisory Council.